Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30258093 | 0.99 | CRBN (0.40) | CRBNDDB1MAPK14BRPF1QDPR | |
| SCHEMBL30258121 | 0.84 | CRBN (0.37) | CRBNDDB1MAPK14TRIM24DRD2 | |
| SCHEMBL23540956 | 0.82 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL22502622 | 0.82 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL31160719 | 0.82 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL30258214 | 0.81 | DRD2 (0.38) | CRBNDDB1DRD2SLC6A4DRD3 | |
| Hydrochloric Acid SCHEMBL27178974 | 0.81 | CRBN (0.62) | CRBNDDB1 | |
| SCHEMBL31282200 | 0.81 | DDB1 (0.40) | CRBNDDB1HTR2C | |
| Hydrochloric Acid SCHEMBL30258751 | 0.81 | DRD2 (0.37) | CRBNDDB1DRD2SLC6A4DRD3 | |
| Hydrochloric Acid SCHEMBL30893198 | 0.79 | CRBN (0.46) | CRBNDDB1BRPF1KHKDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023059792-A1 | CORONAVIRUS NON-STRUCTURAL PROTEIN 3 DEGRADING COMPOUNDS | C4 THRAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CRBN 39/4885DDB1 511/4885MAPK14 1055/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CRBN 79/4885DDB1 2480/4885MAPK14 1773/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885MAPK14 1845/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | CRBN 322/4885DDB1 68/4885MAPK14 1330/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885MAPK14 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.